If CD12 performs similar to CD10 NEWS2 score over placebo, the p value would be less than .02 at the interim assuming a 20% mortality rate of placebo. To achieve statistical power of 80% at the interim mortality rate has to be a lot higher unfortunately for the trial to be stopped. DSMC would most likely recommend trial to continue but CYDY can afford to share results and pay a penalty imho.